 The medical experts have made recommendations on how to improve health financing and ensure efficiency in Nigeria. Now these came up on the sidelines of a continuing medical education program in Lagos, where the theme healthcare diversification in a developing economy details in this report. The way a country finances a healthcare system is a critical determinant for region universal health coverage. In Nigeria, the health sector is financed through different sources and mechanisms. Unfortunately, achieving the correct plan remains a challenge. Medical experts have converged on their CME maintenance put together by CLEMA Lancet to tackle some of the inherent challenges. Access to healthcare, interdisciplinary collaboration, as well as medical assets financing, takes center stage. We know that most of the patients in Nigeria, about 70% of them are out of pocket. But there are initiatives that have been in place. We've always had health insurance. We have donors as well, and the government has also earmarked the basic healthcare fund that they've put in place to be able to help the citizen to access it. So apart from budgetary allocation, these are areas and ways that we can now see that the government as well, and even the private sector is trying to synergize and help to ensure that the citizens are able to afford healthcare. There are lots of healthcare enthusiasts that do not even have access to the right funding, thereby not being able to set up the kind of standard that they probably want to set up, not being able to, you know, the kind of technology or equipment, modern equipment that's necessary for a start-up healthcare organization. So basically in the medical laboratory space where we play, over the years there's been improvement, there's been a lot of entrance. The professionals does course on cancer management in Nigeria. It's efficiency and the need to ensure standardization in the medical laboratory science space. It is that go into determining what we now talk about in cancer case, individualized, personalized treatment. And it means that if Mr. A and Mr. B have a particular cancer, because of their genetic makeup, they will not manifest the cancer in the same way, and they may necessarily not benefit from the same treatment. So those are the things that will be updating the community about that. Cancer is not one disease, but it is a heterogeneous disease. And for the laboratory, what is expected is the ISO 15189, the 2012 version. Now today they go, the 2022 version was just published. So it gives room for additional provisions for the capturing of the quality standard. So when you understand the quality standard, now you begin to look at it. How can we implement it? So the implementation of it is key. Now some of the challenges include the ability for us to understand what is expected from us. Two personnel that have this quality management system as part of the infrastructure technology to ensure that this is done. And with the rate of doing currently in the country, a lot of our experts who are training are moving across the country. There is a dire need to ensure that resources are used more efficiently, while at the same time removing financial barriers by shifting focus from out-of-pocket payments, OOPs, to order-heating resources. And don't forget to hit the notification button so you get notified about fresh news updates.